Home » Stocks » VCNX

Vaccinex, Inc. (VCNX)

Stock Price: $2.55 USD -0.12 (-4.49%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $2.60 +0.05 (1.96%) Jan 22, 7:43 PM
Market Cap 57.08M
Revenue (ttm) 625,000
Net Income (ttm) -28.73M
Shares Out 20.07M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.55
Previous Close $2.67
Change ($) -0.12
Change (%) -4.49%
Day's Open 2.75
Day's Range 2.51 - 2.85
Day's Volume 1,337,296
52-Week Range 1.66 - 8.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, BLCM, LMNL, QFIN, VIVO
GlobeNewsWire - 2 weeks ago

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegene...

GlobeNewsWire - 2 months ago

Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)

GlobeNewsWire - 2 months ago

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

GlobeNewsWire - 2 months ago

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

GlobeNewsWire - 2 months ago

Live moderated video webcast discussion between members of management and Key Opinion Leader, Eric Siemers, MD on Tuesday, October 27th at 10:00 a.m. EDT Live moderated video webcast discussio...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.

Benzinga - 4 months ago

Shares of micro-cap immunotherapy company Vaccinex Inc (NASDAQ: VCNX) were plunging Tuesday in reaction to an adverse readout.

Market Watch - 4 months ago

Shares of Vaccinex Inc. tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet ...

GlobeNewsWire - 4 months ago

K ey cognitive endpoint s trending towards but did not reach statistical significance in early manifest population . O verall study does not meet pre-specified co- primary endpoints

GlobeNewsWire - 4 months ago

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative...

GlobeNewsWire - 4 months ago

ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s d...

Zacks Investment Research - 5 months ago

Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October

Zacks Investment Research - 5 months ago

Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 6 months ago

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, BLRX, PTI, VIVE
Zacks Investment Research - 6 months ago

Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

Topline data anticipated in October 2020 as previously guided Topline data anticipated in October 2020 as previously guided

GlobeNewsWire - 7 months ago

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session

Zacks Investment Research - 8 months ago

Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

Approaching key topline data in non-small cell lung cancer and Huntington’s disease

GlobeNewsWire - 8 months ago

Data continue to demonstrate durable response in patients as trial nears completion Data continue to demonstrate durable response in patients as trial nears completion

Zacks Investment Research - 8 months ago

Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

Updated data continue to demonstrate a durable clinical benefit in both immunotherapy-naïve patients as well as those previously treated with an immunotherapy regimen Updated data continue to ...

GlobeNewsWire - 9 months ago

Presentation highlighted the potential of the company’s lead candidate, the anti-SEMA4D antibody pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntingto...

GlobeNewsWire - 9 months ago

Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data K...

GlobeNewsWire - 1 year ago

Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease P...

GlobeNewsWire - 1 year ago

ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Hu...

GlobeNewsWire - 1 year ago

ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Hu...

Zacks Investment Research - 1 year ago

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

GuruFocus - 1 year ago

President and CEO of Vaccinex Inc (30-Year Financial, Insider Trades) Maurice Zauderer (insider trades) bought 183,824 shares of VCNX on 07/30/2019 at an average price of $4.08 a share.

About VCNX

Vaccinex, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is i... [Read more...]

Industry
Biotechnology
Founded
2001
CEO
Dr. Maurice Zauderer
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
VCNX
Full Company Profile

Financial Performance

In 2019, Vaccinex's revenue was $523,000, a decrease of -27.76% compared to the previous year's $724,000. Losses were -$31.86 million, 7.94% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Vaccinex stock is "Buy." The 12-month stock price forecast is 13.50, which is an increase of 429.41% from the latest price.

Price Target
$13.50
(429.41% upside)
Analyst Consensus: Buy